Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,829.49 -47.56 (-0.60%) Bitcoin USD
64,974.79 +2,884.04 (+4.64%) CMC Crypto 200
1,331.03 +18.41 (+1.42%)
Precision BioSciences, Inc. (DTIL)
Pre-market:
| Previous close | 11.51 |
| Open | 11.41 |
| Bid | 10.69 x 200 |
| Ask | 10.83 x 100 |
| Day's range | 10.71 - 11.66 |
| 52-week range | 8.25 - 27.90 |
| Volume | |
| Avg. volume | 127,183 |
| Market cap | 74.142M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -332.12 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.80 |
ZacksIntra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Business WirePrecision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
DURHAM, N.C., April 16, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration. Precision uses its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated g
ZacksPrecision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
